Evidence map›Paper›PMID 28663285›Full record

ArticleDrug metabolism and disposition: the biological fate of chemicals2017

Inhibitory Effects of Selected Antituberculosis Drugs on Common Human Hepatic Cytochrome P450 and UDP-glucuronosyltransferase Enzymes.

Lei Cao, David J Greenblatt, Awewura Kwara

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug metabolism and disposition: the biological fate of chemicals, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 22 citations in OpenAlex.

  1. Trial
  2. Review
  3. [Interactions between common drug metabolism and precautions for drug usage in Gilbert syndrome].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025
    Review
  4. Article
  5. Review
  6. Polymorphism ofPharmacogenomics · 2024
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Lei CaoGraduate Program in Pharmacology and Experimental Therapeutics, Sackler School of Graduate Biomedical Sciences (L.C., D.J.G.) and Department of Integrative Physiology and Pathobiology (D.J.G.), Tufts University School of Medicine, Boston, Massachusetts; Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island (A.K.); and The Miriam Hospital, Providence, Rhode Island (A.K.).
David J GreenblattGraduate Program in Pharmacology and Experimental Therapeutics, Sackler School of Graduate Biomedical Sciences (L.C., D.J.G.) and Department of Integrative Physiology and Pathobiology (D.J.G.), Tufts University School of Medicine, Boston, Massachusetts; Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island (A.K.); and The Miriam Hospital, Providence, Rhode Island (A.K.) DJ.Greenblatt@Tufts.edu.
Awewura KwaraGraduate Program in Pharmacology and Experimental Therapeutics, Sackler School of Graduate Biomedical Sciences (L.C., D.J.G.) and Department of Integrative Physiology and Pathobiology (D.J.G.), Tufts University School of Medicine, Boston, Massachusetts; Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island (A.K.); and The Miriam Hospital, Providence, Rhode Island (A.K.).
Tufts University · USMiriam Hospital · US

Funding

Pharmacokinetics of Anti-tuberculosis and Antiretroviral Drugs in ChildrenR01HD071779 · NICHD · UNIVERSITY OF FLORIDA · PI KWARA, AWEWURA JACOB · 2012 to 2022
$6.0M
NICHD NIH HHS R01 HD071779
6 · The paper itself

Abstract

The comorbidities of tuberculosis and diseases such as HIV require long-term treatment with multiple medications. Despite substantial in vitro and in vivo information on effects of rifampicin and isoniazid on human CYPs, there is limited published data regarding the inhibitory effects of other anti-TB drugs on human CYPs and UGTs. The inhibitory effects of five first-line anti-TB drugs (isoniazid, rifampicin, pyrazinamide, ethambutol, and rifabutin), and the newly approved bedaquiline, were evaluated for six common human hepatic UGT enzymes (UGT1A1, 1A4, 1A6, 1A9, 2B7 and 2B15) in vitro using HLMs. Pyrazinamide, ethambutol, rifabutin and bedaquiline were also studied for their inhibitory effects on eight of the most common human CYP enzymes (CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A). Rifabutin inhibited multiple CYPs to varying degrees in vitro, but with all IC

Indexed as

AcetaminophenAntitubercular AgentsCytochrome P-450 Enzyme InhibitorsCytochrome P-450 Enzyme SystemDiarylquinolinesEnzyme InhibitorsEthambutolGlucuronosyltransferaseHumansInhibitory Concentration 50IsoenzymesIsoniazidKineticsLiverPyrazinamideRifabutinAcetaminophenAntitubercular AgentsbedaquilineCytochrome P-450 Enzyme InhibitorsCytochrome P-450 Enzyme SystemDiarylquinolinesEnzyme InhibitorsEthambutolGlucuronosyltransferaseIsoenzymesIsoniazidPyrazinamideRifabutin

Identifiers

PMID28663285
PMCPMC5554070
OpenAlexW2725505139

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.